Sandoz: USD 2.1 billion (+19%, +10% lc) Solid growth in key markets was in line with the consistent pace throughout 2009, with completion of the EBEWE Pharma acquisition in September adding five percentage points of growth in the 2009 quarter.
Sandoz: USD 2,1 milliards (+19%, +10% en m. l).
